WEGOVY (semaglutide)
DIET AIDS·WEIGHT LOSS MANAGEMENT FOR OBESE PATIENT (BODY MASS INDEX 30 OR GREATER)·+3
NOVO NORDISK
Indication
Nonalcoholic steatohepatitis
Nonalcoholic steatohepatitis is an advanced, progressive subtype of nonalcoholic fatty liver disease affecting the hepatic system, predominantly occurring in individuals with obesity, insulin resistance, type 2 diabetes, or metabolic syndrome in the absence of significant alcohol consumption. Read more about Nonalcoholic steatohepatitis
3 drugs 2 manufacturers
Drugs that treat it
Common Nonalcoholic steatohepatitis therapies.
WEGOVY (semaglutide)
DIET AIDS·WEIGHT LOSS MANAGEMENT FOR OBESE PATIENT (BODY MASS INDEX 30 OR GREATER)·+3
A-S MEDICATION
WEGOVY HD (semaglutide)
DIET AIDS·WEIGHT LOSS MANAGEMENT FOR OBESE PATIENT (BODY MASS INDEX 30 OR GREATER)·+3
NOVO NORDISK
Filter & compare in the drug finder →Opens the drug finder with Nonalcoholic steatohepatitis preselected.
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonNonalcoholic steatohepatitis is an advanced, progressive subtype of nonalcoholic fatty liver disease affecting the hepatic system, predominantly occurring in individuals with obesity, insulin resistance, type 2 diabetes, or metabolic syndrome in the absence of significant alcohol consumption.
It is histopathologically defined by hepatic steatosis accompanied by lobular inflammation and hepatocyte injury, notably ballooning degeneration, with or without associated fibrosis.
Pathophysiologically driven by lipotoxicity, oxidative stress, and immune-mediated inflammatory cascades, this condition carries a substantial risk of progressing to advanced fibrosis, cirrhosis, end-stage liver failure, and hepatocellular carcinoma.
- nih.gov
Nonalcoholic steatohepatitis is an advanced, progressive subtype of nonalcoholic fatty liver disease affecting the hepatic system, predominantly occurring in individuals with obesity, insulin resistance, type 2 diabetes, or metabolic syndrome in the absence of significant alcohol consumption Pathophysiologically driven by lipotoxicity, oxidative stress, and immune-mediated inflammatory cascades, this condition carries a substantial risk of progressing to advanced fibrosis, cirrhosis, end-stage l...
- nih.gov
Nonalcoholic steatohepatitis is an advanced, progressive subtype of nonalcoholic fatty liver disease affecting the hepatic system, predominantly occurring in individuals with obesity, insulin resistance, type 2 diabetes, or metabolic syndrome in the absence of significant alcohol consumption It is histopathologically defined by hepatic steatosis accompanied by lobular inflammation and hepatocyte injury, notably ballooning degeneration, with or without associated fibrosis Pathophysiologically dri...
- nih.gov
Nonalcoholic steatohepatitis is an advanced, progressive subtype of nonalcoholic fatty liver disease affecting the hepatic system, predominantly occurring in individuals with obesity, insulin resistance, type 2 diabetes, or metabolic syndrome in the absence of significant alcohol consumption
- nih.gov
It is histopathologically defined by hepatic steatosis accompanied by lobular inflammation and hepatocyte injury, notably ballooning degeneration, with or without associated fibrosis
- nih.gov
Pathophysiologically driven by lipotoxicity, oxidative stress, and immune-mediated inflammatory cascades, this condition carries a substantial risk of progressing to advanced fibrosis, cirrhosis, end-stage liver failure, and hepatocellular carcinoma
Personalize your experience
Follow Nonalcoholic steatohepatitis and get updates as they land.
Create a free account
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.